Embolization Product Market Research, 2033
The embolization product market size was valued at $9.2 billion in 2023 and is estimated to reach $14.9 billion by 2035, exhibiting a CAGR of 5% from 2024 to 2033.
Growth of the embolization product market is driven by rise in prevalence of chronic diseases such as cancer, liver disorders, and vascular malformations, which require minimally invasive treatment options. According to a 2024 article by Brain Aneurysm Foundation, around 1 in 50 peoples in U.S. has an unruptured brain aneurysm. Rise in demand for image-guided procedures and advancements in interventional radiology have further propelled the adoption of embolization techniques. In addition, growing geriatric population, which is more prone to conditions requiring embolization, contributes to market expansion.
Key Takeaways
- By product, the embolic coil segment was largest contributor to the market in 2023. However, the embolic plug system segment is expected to register highest CAGR during the forecast period
- By procedure, the transcatheter arterial embolization (TAE) segment is largest contributor to the market in 2023 and is expected to register the highest CAGR during the forecast period.
- By application, the peripheral segment was the largest contributor to the market in 2023. However, the neurovascular segment is expected to register the highest CAGR during the forecast period.
- Region-wise, Asia-Pacific generated the largest revenue in 2023. However, Latin America is anticipated to grow at the highest CAGR during the forecast period.
Embolization products are medical devices used in minimally invasive procedures to block blood vessels and control or stop abnormal bleeding, manage tumors, or treat vascular conditions such as aneurysms and arteriovenous malformations (AVMs). Embolization products work by deliberately obstructing blood flow to a specific area of the body, either temporarily or permanently, depending on the clinical need.
Market Dynamics
Growth of the embolization product market is primarily driven by rise in prevalence of chronic conditions such as cancer, liver disease, and vascular malformations, which often require minimally invasive treatment procedures. According to the National Cancer Institute, there were almost 20 million new cases in 2022. Embolization procedures, particularly transarterial chemoembolization (TACE) and radioembolization, are widely used to treat inoperable tumors by blocking blood flow to cancerous tissues, thereby starving them of nutrients and oxygen. Embolization procedures are especially critical in managing liver cancer, kidney cancer, and certain types of neuroendocrine tumors, where conventional surgery may not be viable.
As cancer incidence continues to grow globally due to factors such as aging populations, lifestyle changes, and environmental influences, healthcare providers are increasingly turning to embolization as a cost-effective and less invasive alternative to open surgery.
Rise in demand for minimally invasive surgeries is a major driver for the embolization product market growth, as these procedures offer numerous advantages over traditional open surgeries. Patients and healthcare providers are increasingly favoring minimally invasive techniques due to reduced hospital stays, lower risk of complications, shorter recovery times, and decreased postoperative pain. Embolization, a key minimally invasive procedure, is widely used in the treatment of conditions such as aneurysms, uterine fibroids, arteriovenous malformations, and certain types of cancer.
Rise in the geriatric population serves as a major driver for the embolization product market due to rise inprevalence of age-related medical conditions that often require minimally invasive treatment approaches. According to the World Health Organization, 1 in 6 people in the world will be aged 60 years or over by 2030. Older adults are more susceptible to chronic disorders such as cancer, cardiovascular diseases, and vascular malformations, all of which are key indications for embolization procedures. Embolization offers a less invasive alternative to traditional surgery, which is particularly advantageous for elderly patients who may have multiple comorbidities and are at higher risk during open surgical interventions. In addition, the aging population often requires repeated or long-term management of these conditions, leading to rise in demand for effective, safe, and repeatable procedures—further boosting the adoption of embolization products. As life expectancy increases globally, healthcare systems are placing greater emphasis on interventions that can improve quality of life while minimizing hospital stays and recovery time, making embolization therapies a preferred choice in geriatric care.
In addition, technological advancements represent a major opportunity for growth in the embolization product market, as they are driving innovation and improving the efficacy, safety, and precision of embolization procedures. The development of next-generation embolic agents, such as radiopaque and drug-eluting beads, enables real-time imaging and targeted drug delivery, enhancing treatment outcomes for patients with conditions such as hepatocellular carcinoma or uterine fibroids. According to a 2025 article by American Cancer Society, Trans-arterial chemoembolization (TACE) is usually the first type of embolization used for large liver cancers that cannot be treated with surgery or ablation. It combines embolization with chemotherapy.
Drug-eluting bead chemoembolization (DEB-TACE) combines TACE with drug-eluting beads (tiny beads that contain a chemo drug). The procedure is essentially the same as TACE except that the artery is blocked after drug-eluting beads are injected. As chemo is physically close to cancer and as the drug-eluting beads slowly release the chemo, the cancer cells are more likely to be damaged and die.
Segmental Overview
The embolization products market is segmented on the basis of product, procedure, application, and region. On the basis of product, the market is divided into embolic coils, embolic agents, and detachable balloons. On the basis of procedure, the market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization (TARE), and transarterial chemoembolization (TACE). On the basis of application, the market is segmented into neurovascular and peripheral. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, U.K, and Rest of Europe), Asia-Pacific (China, Japan, and India), and Latin America (Brazil, Chile, Peru, and Rest of Latin America), and Middle East (Morocco, Nigeria, South Africa, Saudi Arabia, and Rest of MEA).
By Product
The embolic coils segment dominated the embolization product market share in 2023, as embolic coils are extensively used in the treatment of cerebral aneurysms, arteriovenous malformations (AVMs), and various forms of internal bleeding, making them a preferred choice among interventional radiologists and neurosurgeons. Rise in prevalence of neurovascular disorders and cardiovascular conditions has significantly increased the demand for effective embolization procedures, further driving the adoption of embolic coils. However, embolic plug system is expected to register highest CAGR during the forecast period owing to its minimally invasive nature, high precision, and growing clinical adoption in treating a variety of conditions such as arteriovenous malformations (AVMs), aneurysms, and peripheral vascular diseases.
By Product
Embolic coil segment held a dominant position in the market in 2023 and embolic plug system segment is anticipated to grow at a fastest rate during the forecast period.
By Procedure
The transcatheter arterial embolization (TAE ) segment dominated the market in terms of revenue in 2023, attributed to its minimally invasive nature, high efficacy in controlling bleeding, and expanding applications across various medical conditions. TAE is widely utilized in the treatment of tumors, gastrointestinal bleeding, and traumatic injuries, offering a safer alternative to traditional surgical interventions. Its growing adoption is also driven by rise in awareness among healthcare professionals and patients about the benefits of embolization procedures, including reduced recovery time, lower risk of complications, and shorter hospital stays.
By Procedure
Transcatheter Arterial Embolization (TAE) segment held a dominant position in the market in 2023 and is anticipated to grow at a fastest rate during the forecast period.
By Application
The peripheral segment dominated the market in terms of revenue in 2023. This is attributed to rise in prevalence of peripheral vascular diseases (PVDs) and increase in demand for minimally invasive treatment options. Peripheral embolization procedures are widely used to manage conditions such as arteriovenous malformations, aneurysms, and uncontrolled bleeding in the peripheral vasculature, which are increasingly diagnosed thanks to improvements in imaging technologies. However, the neurovascular segment is expected to register highest CAGR in the forecast period. This is attributed to increasing prevalence of neurovascular disorders such as stroke, cerebral aneurysms, and arteriovenous malformations. Technological advancements in imaging, catheter design, and embolic materials have further enhanced the success rates and safety of these procedures, contributing to their rising demand.
By Application
Peripheral segment held a dominant position in the market in 2023 and However, neurovascular segment is anticipated to grow at a fastest rate during the forecast period.
By Region
The embolization product market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia Pacific has emerged as a major revenue generator in the embolization products market due to a combination of rising healthcare expenditure, increasing prevalence of chronic conditions such as cancer and vascular diseases, and rapid advancements in medical infrastructure across the region. Countries like China, India, Japan, and South Korea are witnessing a surge in demand for minimally invasive procedures, including embolization, as patients and healthcare providers increasingly prioritize shorter recovery times and reduced procedural risks. Additionally, the growing elderly population, which is more susceptible to conditions requiring embolization therapies, has contributed to the rising adoption of these products. Government initiatives aimed at enhancing healthcare accessibility and increasing the number of interventional radiology procedures performed across urban and semi-urban hospitals further drive regional market growth.
However, Latin Americ is expected to grow at the highest rate during the forecast period, owing to developing healthcare infrastructure and funding from government and non-government organization.
Competition Analysis
Major key players that operate in the global embolization product market are Cook Medical, Medtronic Plc, Stryker Corporation, Penumbra Inc, Boston Scientific Corporation, Johnson and Johnson, Terumo Corp, Sirtex Medical Limited, Meril Life Sciences Pvt. Ltd., and Balt Group. Key players operating in the market have adopted product launch as their key strategies to expand their product portfolio.
Recent Developments in the Embolization Product Industry
- In December 2023, Terumo Corporation announced the launch of AZUR HydroPack Peripheral Coil System in the U.S. The AZUR HydroPack Coil System is a soft, universal-shaped platinum and hydrogel coil designed to find and fill empty space within the vessel. The AZUR HydroPack Peripheral Coil System provides optimized stability and precise delivery. Its versatility and efficiency provide interventional radiologists and vascular surgeons with an ideal solution to ensure the best possible outcome for patients.
- In June 2022, Johnson and Johnson announced the launch of Trufill n-BCA Liquid Embolic System Procedural Set. The latest addition to the CERENOVUS hemorrhagic stroke portfolio offers Trufill n-BCA Liquid Embolic System as a new procedural set that includes two configurations and the accessories needed to prep and deliver n-BCA Liquid Embolic System in one sterilized set, creating streamlined procedure preparation.
Analyst Review
This section provides various opinions of top-level CXOs in the embolization products market. According to the insights of CXOs, the embolization products market has witnessed a steady rise in demand, primarily driven by developing healthcare infrastructure especially in low-income countries, increase in prevalence of vascular diseases, and rise in aging population. Furthermore, technological innovations, such as advanced materials and delivery systems, are enhancing the efficacy and safety of these products, further propelling the market growth. In addition, rise in adoption of minimally invasive procedures is expected to contribute significantly to the growth of the market, as these techniques offer reduced recovery times, lower risk of complications, and overall improved patient outcomes as compared to traditional surgical methods. The shift towards less invasive approaches is significantly boosting demand for advanced embolization products, thus driving market growth.
The forecast period for embolization product market is 2024-2033.
The embolization products market was valued at $ 9.2 billion in 2023
The market value of embolization product market is estimated to reach $14.9 billion by 2033
The base year is 2023 in embolization product market
Major key players that operate in the embolization product market are Cook Medical, Medtronic Plc, Stryker Corporation, Penumbra Inc, Boston Scientific Corporation
The embolization product market growth is driven by rise in prevalence of chronic diseases such as cancer, liver disorders, and vascular malformations, which require minimally invasive treatment options.
Embolization products are medical devices used to intentionally block or reduce blood flow in specific blood vessels. These products are commonly employed in minimally invasive procedures known as embolization, which aim to treat a variety of conditions such as tumors, aneurysms, arteriovenous malformations, and internal bleeding. By obstructing the targeted blood vessels, embolization helps cut off the blood supply to abnormal or damaged tissue, aiding in its shrinkage or removal. The main types of embolization products include embolic agents like coils, microspheres, plugs, and liquid embolics, each tailored to specific clinical needs and vessel sizes. These products are typically delivered via catheter through a guided imaging technique, making the procedure less invasive than traditional surgery.
Loading Table Of Content...
